Impact of a VA-ECMO in combination with an extracorporeal cytokine hemadsorption system in critically ill patients with cardiogenic shock.A prospective, randomized, controlled, blinded, monocenter, trial - ECMOsorb

niversitätsklinikum Jena KIM I, Kardiologie0 个研究点目标入组 54 人开始时间: 2021年5月12日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Critically ill patients with cardiogenic shock with or without reanimation (CPR),
•- indication for VA-ECMO,
•- age =18 years =80 years.
•- signed informed consent

•Contraindications to VA-ECMO implantation.
•Patients with pre – existing sepsis (raised CRP, positive PCT, leukocytosis, fever, positive blood cultures).
•Shock duration> 12 h before evaluation.
•Severe PVD (peripheral vessel disease) making ECMO-implantation impossible.
•Aortic valve insufficiency / stenosis at least II °.
•Age <18, > 80 years.
•CNS disease with fixed, dilated pupils (not drug-induced).
•Severe concomitant disease with limited life expectancy <6 months.
•Participation in another study.
•CPR> 60min.
•Shock due to other reasons.
•Pregnancy.
•HIT positive (Heparin induced thrombocytopenia).
•Very low platelet counts (< 20,000/µL).
•Body weight less than 45 kg
•Current immunosuppressive or immunomodulatory therapy

发起方

niversitätsklinikum Jena KIM I, Kardiologie